Alejandro Cendejas-Higuera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alejandro Cendejas-Higuera has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ana Cantu-Zendejas
Medical Doctor, Christus Muguerza Hospital, Monterrey, Nuevo Leon, Mexico
2 shared publications - Mario Riquelme
Christus Muguerza Hospital, Monterrey, Mexico
2 shared publications Arsenio Hernandez-Flota
Pediatric Surgeon, General Dr. Agustin O'Horan Hospital, Merida, Yucatan, Mexico
1 shared publicationCarlos Garcia-Hernandez
1 shared publication- Carlos García-Hernández
Univ Nacl Autonoma Mexico, Hosp Infantil Privado, Dept Cirugia Pediat, Ciudad De Mexico, Mexico
1 shared publication - Daniel Aillaud‐De‐Uriarte
Center for Bioethics Harvard Medical School Boston Massachusetts USA
1 shared publication
Latest Publications
- 3 December 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (3) , 162860
Laparoscopic inguinal sac resection (LISAR): A multicenter retrospective case series over two decades in pediatric hernia repair
- 3 December 2025
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 61 (3) , 162860
Laparoscopic inguinal sac resection (LISAR): A multicenter retrospective case series over two decades in pediatric hernia repair
- Open Access
- 1 December 2025
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 1, e12
Evaluating ChatGPT-5o as a Clinical Decision-Support Tool in Inflammatory Bowel Disease: A Pilot Study of Guideline Adherence and Clinical Agreement
Background: Inflammatory bowel disease (IBD) presents complex management challenges. While care is guided by expertise and guidelines, artificial intelligence (AI) is being explored as an adjunct. This study evaluates ChatGPT-5o’s ability to provide IBD recommendations by comparing its outputs with real-world decisions and European Crohn’s and Colitis Organisation (ECCO) guidelines. Methods: We performed a retrospective analysis of 19 anonymized IBD cases spanning initial and complicated disease. ChatGPT-5o generated management recommendations, which were compared with clinician treatments and ECCO guidelines across seven therapeutic domains (5-aminosalicylic acid (5-ASA), steroids, antibiotics, thiopurines, anti-tumor necrosis factor (TNF), anti-integrins, anti-interleukin-23 (IL-23)) plus diagnostic workup, symptom management, surgical consultation, and monitoring. Agreement was quantified using Cohen’s Kappa. Results: ChatGPT-5o showed perfect agreement (κ = 1.000) with providers and/or guidelines for antibiotics, diagnostic workup, symptom management, surgical consultation, monitoring, and anti-IL-23. Substantial agreement (κ ≈ 0.6 - 0.8) was observed for 5-ASA and steroids. Moderate to fair agreement (κ ≈ 0.3 - 0.5) occurred for anti-TNF and anti-integrins, reflecting variability in complex scenarios. Thiopurines demonstrated the lowest concordance, with none-to-slight agreement in human-AI comparisons but higher alignment of ChatGPT-5o with ECCO, suggesting evolving practice patterns and safety considerations. Conclusions: ChatGPT-5o closely aligns with clinicians and ECCO guidelines in multiple standardized domains, supporting its potential as a decision-support tool to enhance guideline adherence and broaden access to IBD expertise. Variability in biologic selection and thiopurine use underscores the need for expert oversight and patient-specific judgment. Prospective studies should assess longitudinal outcomes and integration strategies to ensure safe, patient-centered deployment.
- 1 December 2025
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 1, e12
Open AccessEvaluating ChatGPT-5o as a Clinical Decision-Support Tool in Inflammatory Bowel Disease: A Pilot Study of Guideline Adherence and Clinical Agreement
Background: Inflammatory bowel disease (IBD) presents complex management challenges. While care is guided by expertise and guidelines, artificial intelligence (AI) is being explored as an adjunct. This study evaluates ChatGPT-5o’s ability to provide IBD recommendations by comparing its outputs with real-world decisions and European Crohn’s and Colitis Organisation (ECCO) guidelines. Methods: We performed a retrospective analysis of 19 anonymized IBD cases spanning initial and complicated disease. ChatGPT-5o generated management recommendations, which were compared with clinician treatments and ECCO guidelines across seven therapeutic domains (5-aminosalicylic acid (5-ASA), steroids, antibiotics, thiopurines, anti-tumor necrosis factor (TNF), anti-integrins, anti-interleukin-23 (IL-23)) plus diagnostic workup, symptom management, surgical consultation, and monitoring. Agreement was quantified using Cohen’s Kappa. Results: ChatGPT-5o showed perfect agreement (κ = 1.000) with providers and/or guidelines for antibiotics, diagnostic workup, symptom management, surgical consultation, monitoring, and anti-IL-23. Substantial agreement (κ ≈ 0.6 - 0.8) was observed for 5-ASA and steroids. Moderate to fair agreement (κ ≈ 0.3 - 0.5) occurred for anti-TNF and anti-integrins, reflecting variability in complex scenarios. Thiopurines demonstrated the lowest concordance, with none-to-slight agreement in human-AI comparisons but higher alignment of ChatGPT-5o with ECCO, suggesting evolving practice patterns and safety considerations. Conclusions: ChatGPT-5o closely aligns with clinicians and ECCO guidelines in multiple standardized domains, supporting its potential as a decision-support tool to enhance guideline adherence and broaden access to IBD expertise. Variability in biologic selection and thiopurine use underscores the need for expert oversight and patient-specific judgment. Prospective studies should assess longitudinal outcomes and integration strategies to ensure safe, patient-centered deployment.
- Open Access
- 19 December 2024
- Published by Elsevier in Journal of Pediatric Surgery Open
- Vol. 10
Efficacy and safety of retrograde laparoscopic appendectomy in pediatric complicated appendicitis: A 14- year retrospective analysis
- 19 December 2024
- Published by Elsevier in Journal of Pediatric Surgery Open
- Vol. 10
Open AccessEfficacy and safety of retrograde laparoscopic appendectomy in pediatric complicated appendicitis: A 14- year retrospective analysis